Chimeric Therapeutics Ltd (CHM) - Total Liabilities
Based on the latest financial reports, Chimeric Therapeutics Ltd (CHM) has total liabilities worth AU$8.96 Million AUD (≈ $6.34 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Chimeric Therapeutics Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Chimeric Therapeutics Ltd - Total Liabilities Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Chimeric Therapeutics Ltd (CHM) total assets.
Chimeric Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Chimeric Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ellwee AB
ST:ELLWEE
|
Sweden | Skr14.87 Million |
|
GO METALS CORP.
F:47GA
|
Germany | €75.37K |
|
ImmuPharma PLC
LSE:IMM
|
UK | GBX1.24 Million |
|
VOLTAGE METALS CORP.
F:8L10
|
Germany | €1.66 Million |
|
EV Digital Invest AG
F:ENGL
|
Germany | €1.32 Million |
|
HPI AG
MU:CEW3
|
Germany | €38.52 Million |
|
Investor Centre Ltd
AU:ICU
|
Australia | AU$3.25 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Chimeric Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Chimeric Therapeutics Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.34 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chimeric Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chimeric Therapeutics Ltd (2020–2025)
The table below shows the annual total liabilities of Chimeric Therapeutics Ltd from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$19.60 Million ≈ $13.87 Million |
+53.06% |
| 2024-06-30 | AU$12.80 Million ≈ $9.06 Million |
-23.40% |
| 2023-06-30 | AU$16.71 Million ≈ $11.83 Million |
+82.21% |
| 2022-06-30 | AU$9.17 Million ≈ $6.49 Million |
-19.35% |
| 2021-06-30 | AU$11.37 Million ≈ $8.05 Million |
+17670.20% |
| 2020-06-30 | AU$64.01K ≈ $45.29K |
-- |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more